Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Shyam, Srivats"'
Autor:
Antoni Ribas, Mohammed Milhem, Diwakar Davar, Patricia LoRusso, Zeynep Eroglu, Martin Gutierrez, Arindam Dhar, Carlos Becerra, Brian Di Pace, Tianli Wang, Hailei Zhang, Srimoyee Ghosh, Shyam Srivats, Theo Borgovan, Angela Waszak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/124fe11cbcbd49b981727309c6d8f1f9
Autor:
Qi Wang, Heba Alshaker, Torsten Böhler, Shyam Srivats, Yimin Chao, Colin Cooper, Dmitri Pchejetski
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Abstract Many prostate cancers relapse after initial chemotherapy treatment. Combining molecular and chemotherapy together with encapsulation of drugs in nanocarriers provides effective drug delivery and toxicity reduction. We developed core shell li
Externí odkaz:
https://doaj.org/article/beda79c1f26c4da98ebe53b6842a492f
Autor:
Namrata Patil, Raymond Meng, Robert Johnston, Patrick Chang, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Thinh Pham, Alexis Dunkle, Bill O’Gorman, Ira Mellman, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil Bazo, Enriqueta Felip, Sanjeev Mariathasan, Carlos Bais, David Shames
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Namrata S. Patil, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Alexis Dunkle, Bill O’Gorman, Patrick S. Chang, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil-Bazo, Enriqueta Felip, Ira Mellman, Raymond Meng, Sanjeev Mariathasan, Robert Johnston, David S. Shames
Publikováno v:
Cancer Research. 83:5712-5712
Background: TIGIT is a co-inhibitory receptor and immune checkpoint associated with T cell and natural killer (NK) cell dysfunction in cancer. Tiragolumab is an anti-TIGIT antibody with an active IgG1/kappa Fc. In a randomized double-blind phase 2 cl
Autor:
Namrata S. Patil, Barzin Y. Nabet, Sören Müller, Hartmut Koeppen, Wei Zou, Jennifer Giltnane, Amelia Au-Yeung, Shyam Srivats, Jason H. Cheng, Chikara Takahashi, Patricia E. de Almeida, Avantika S. Chitre, Jane L. Grogan, Linda Rangell, Sangeeta Jayakar, Maureen Peterson, Allison W. Hsia, William E. O’Gorman, Marcus Ballinger, Romain Banchereau, David S. Shames
Publikováno v:
Cancer Cell. 40:289-300.e4
Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) benefit. Using transcriptomic analysis of 891 NSCLC tumors from
Autor:
Dmitri Pchejetski, Caroline M. R. Low, Danielle Monteil, Heba Alshaker, Shyam Srivats, Qi Wang
Publikováno v:
Breast Cancer Research and Treatment
Purpose Sphingosine kinase 1 (SK1) is a protooncogenic enzyme expressed in many human tumours and is associated with chemoresistance and poor prognosis. It is a potent therapy target and its inhibition chemosensitises solid tumours. Despite recent ad
Publikováno v:
The Journal of Biological Chemistry
Acid-sensing ion channels (ASICs) form both homotrimeric and heterotrimeric ion channels that are activated by extracellular protons and are involved in a wide range of physiological and pathophysiological processes, including pain and anxiety. ASIC
Autor:
J. Michael Edwardson, Colin W. Taylor, Gerard Vistal, Dilshan Balasuriya, Ruth D. Murrell-Lagnado, Shyam Srivats, Mathias Pasche
Publikováno v:
The Journal of Cell Biology
Sigma1 receptors inhibit store-operated Ca2+ entry and reduce the Ca2+ content of the intracellular stores. These effects are regulated by Sigma1 receptor ligands. A ligand-dependent interaction between Sigma1R and STIM1 reduces STIM1 association wit
Publikováno v:
Breast Cancer Research and Treatment
Purpose Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f47dc5fa3e04e07995c6faf227b3dcb
https://ueaeprints.uea.ac.uk/id/eprint/64323/
https://ueaeprints.uea.ac.uk/id/eprint/64323/
Autor:
Yimin Chao, Torsten Böhler, Colin Cooper, Heba Alshaker, Dmitri Pchejetski, Qi Wang, Shyam Srivats
Publikováno v:
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Many prostate cancers relapse after initial chemotherapy treatment. Combining molecular and chemotherapy together with encapsulation of drugs in nanocarriers provides effective drug delivery and toxicity reduction. We developed core shell lipid-polym